Age 0 3 0 3 B-age
6 4 5 4 5 B-lower_bound
months 6 12 6 12 I-lower_bound
to 13 15 13 15 O
21 16 18 16 18 B-upper_bound
years 19 24 19 24 I-upper_bound
at 25 27 25 27 O
the 28 31 28 31 O
time 32 36 32 36 O
of 37 39 37 39 O
enrollment 40 50 40 50 O

Clinical 0 8 51 59 O
decision 9 17 60 68 O
by 18 20 69 71 O
patient 21 28 72 79 O
, 28 29 79 80 O
family 30 36 81 87 O
, 36 37 87 88 O
and 38 41 89 92 O
healthcare 42 52 93 103 O
provider 53 61 104 112 O
to 62 64 113 115 O
initiate 65 73 116 124 O
hydroxyurea 74 85 125 136 B-treatment
therapy 86 93 137 144 I-treatment
, 93 94 144 145 O
including 95 104 146 155 O
patients 105 113 156 164 O
who 114 117 165 168 O
are 118 121 169 172 O
transitioning 122 135 173 186 O
from 136 140 187 191 O
chronic 141 148 192 199 B-treatment
transfusions 149 161 200 212 I-treatment
to 162 164 213 215 O
hydroxyurea 165 176 216 227 O
therapy 177 184 228 235 O

Diagnosis 0 9 236 245 O
of 10 12 246 248 O
sickle 13 19 249 255 B-chronic_disease
cell 20 24 256 260 I-chronic_disease
anemia 25 31 261 267 I-chronic_disease

Family 0 6 268 274 O
unwillingness 7 20 275 288 O
to 21 23 289 291 O
sign 24 28 292 296 O
informed 29 37 297 305 O
consent 38 45 306 313 O
or 46 48 314 316 O
comply 49 55 317 323 O
with 56 60 324 328 O
study 61 66 329 334 O
treatments 67 77 335 345 B-treatment

HbSS 0 4 346 350 B-chronic_disease
or 5 7 351 353 O
HbÎ²0 8 12 354 358 B-chronic_disease
- 12 13 358 359 I-chronic_disease
thalassemia 13 24 359 370 I-chronic_disease

